Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (DE:DUL)
FRANKFURT:DUL
Holding DE:DUL?
Track your performance easily
Earnings Data
Report Date
Feb 06, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-€0.54Last Year’s EPS
-€1.06Same Quarter Last Year
Moderate Buy
Based on 23 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 31, 2024
|% Change Since: -11.46%
|Next Earnings Date:Feb 06, 2025
Earnings Call Sentiment|Positive
The overall sentiment of the earnings call reflects a positive outlook driven by strong revenue growth, significant advancements in the pipeline, and successful regulatory submissions. Despite some challenges such as decreased collaboration revenue and the discontinuation of a development program, the highlights, including record revenue growth and promising pipeline progress, significantly outweigh the lowlights.Company Guidance
During the Q3 2024 earnings call for Alnylam Pharmaceuticals, the company provided guidance reflecting optimism about their financial and strategic direction. Alnylam reported a 34% year-over-year increase in global net product revenue, reaching $420 million, driven by strong performance in both their TTR and rare disease franchises. Their TTR franchise alone generated $309 million, marking a 34% increase from the previous year, with approximately 5,000 patients on treatment worldwide. Additionally, the company reiterated its full-year revenue guidance, projecting combined net product revenues between $1.575 billion and $1.65 billion and collaboration and royalty revenues ranging from $575 million to $650 million. Alnylam also highlighted their advancements in the pipeline, including regulatory submissions for vutrisiran in the U.S. and EU and the launch of a Phase I study for ALN-HTT02 in Huntington's disease. The company remains confident in its trajectory towards achieving sustainable profitability and further developing their innovative RNAi platform.Record Revenue Growth
Alnylam Pharmaceuticals achieved 34% year-over-year growth in global net product revenue, generating $420 million across its 4 marketed products.
TTR Franchise Performance
The TTR franchise achieved $309 million in global net product revenues, representing a 34% increase year-over-year, with significant growth in hATTR polyneuropathy patients, particularly in the U.S.
Pipeline Progress in CNS
Initiated a Phase I study of ALN-HTT02 in Huntington's disease and announced initial results from the multi-dose portion of the Phase I study of mivelsiran in early onset Alzheimer's disease.
Regulatory Advancement in Cardiomyopathy
Completed regulatory submissions for vutrisiran in the U.S. and EU, with additional global submissions planned, supported by compelling HELIOS-B study data.
Strong Royalty Revenue Growth
Royalty revenue for Q3 2024 was $23 million, more than doubling compared to Q3 2023.
---
DE:DUL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DE:DUL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | €261.00 | €256.30 | -1.80% |
| Aug 01, 2024 | €214.80 | €222.10 | +3.40% |
| May 02, 2024 | €136.65 | €138.80 | +1.57% |
| Feb 15, 2024 | €150.40 | €152.20 | +1.20% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Alnylam Pharmaceuticals (DE:DUL) report earnings?
Alnylam Pharmaceuticals (DE:DUL) is schdueled to report earning on Feb 06, 2025, TBA Not Confirmed.
What is Alnylam Pharmaceuticals (DE:DUL) earnings time?
Alnylam Pharmaceuticals (DE:DUL) earnings time is at Feb 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Alnylam Pharmaceuticals stock?
The P/E ratio of Alnylam Pharma is N/A.
What is DE:DUL EPS forecast?
DE:DUL EPS forecast for the fiscal quarter 2024 (Q4) is -€0.54.
---